Minerva Neurosciences | NERV - Debt


Minerva Neurosciences reported $0 in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Adma Biologics USD 204.41M 121.28M Mar/2026
ALKERMES USD 1.58B 1.51B Mar/2026
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
AstraZeneca USD 32.24B 1.68B Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Cipla INR 6.14B 1.76B Mar/2026
Clal Biotechnology ILS 35.76M 28.27M Dec/2023
Compugen USD 2.93M 14K Mar/2026
CSL USD 11.96B 219M Dec/2024
Eli Lilly USD 43.37B 867M Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Grifols EUR 9.23B 626.05M Dec/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
J&J USD 54.99B 7.05B Mar/2026
Merck USD 49.12B 222M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 63.19B 536M Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 23.58B 3.56B Jun/2026
Takeda JPY 4.94T 58.13B Jun/2026
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024